跳至主要内容
临床试验/NL-OMON31280
NL-OMON31280尚未招募2 期

Efficacy and feasibility of the combination of everolimus and capecitabine in patients with metastatic or locally advanced pancreatic carcinoma - everolimus and capecitabine in pancreatic cancer

Academisch Medisch Centrum0 个研究点目标入组 33 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
33

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Signed informed content obtained prior to treatment
  • - Cytological or histological confirmed adenocarcinoma of the pancreas
  • - Metastatic or non-resectable disease
  • - Measurable lesion according to RECIST criteria
  • - ECOG/ WHO performance 0-2
  • - Age > 18 years
  • - Life expectancy > 3 months
  • - Adequate renal function (creatinine < 150 µmol/L)
  • - Adequate liver function (bilirubin < 1.5 times upper limit of normal, ALAT or ASAT < 5.0 times upper limit of normal in case of liver metastases and < 2.5 the upper limit of normal in absence of liver metastases
  • - Adequate bone marrow function (WBC > 3.0 x 10 9/L, platelets > 100 x 10 9/L)
  • - Mentally, physically, and geographically able to undergo treatment and follow up

排除标准

  • - Clinical or radiological evidence of CNS metastases
  • - Pregnancy (positive serum pregnancy test) and lactation
  • - Serious concomitant systemic disorder that would compromise the safety of the patient, at the discretion of the investigator

研究者

相似试验